Edesa Biotech, Inc. — Form 10-Q Summary
Reporting period: Fiscal second quarter and six months ended March 31, 2024. The unaudited statements are in U.S. dollars. Edesa is a clinical-stage biopharmaceutical company developing treatments for inflammatory and immune-related diseases; it reported no product revenue.
Financial performance and position
| Metric | Three months ended March 31 | Six months ended March 31 |
|---|---|---|
| Research and development expense | 2024: $1.18 million; 2023: $1.46 million | 2024: $1.88 million; 2023: $2.82 million |
| General and administrative expense | 2024: $1.04 million; 2023: $0.95 million | 2024: $2.20 million; 2023: $1.97 million |
| Operating loss | 2024: $2.22 million; 2023: $2.41 million | 2024: $4.08 million; 2023: $4.79 million |
| Net loss | 2024: $1.86 million; 2023: $2.33 million | 2024: $3.54 million; 2023: $4.67 million |
| Basic and diluted loss per share | 2024: $0.58; 2023: $0.82 | 2024: $1.12; 2023: $1.70 |
- Cash flow: Net cash used in operations was $3.07 million for the six months, versus $3.36 million a year earlier. Financing provided $0.52 million, compared with $3.68 million, primarily because the prior-year period included a private placement and warrant exercises. Cash declined by $2.56 million to $2.80 million.
- Liquidity and balance sheet: At March 31, cash was $2.80 million, current assets $4.24 million, current liabilities $2.15 million, and working capital $2.1 million. Total assets were $6.48 million and total liabilities $2.15 million. The company had an accumulated deficit of $56.0 million.
- Debt and other obligations: The company reported no drawn balance on its related-party revolving credit facility. It repaid approximately $29,500 of debt during the six-month period. Lease liabilities were $58,143, all current. The new Canadian government SIF funding includes up to C$17.2 million conditionally repayable beginning in 2029 if the company earns gross revenue; up to C$5.8 million is nonrepayable.
- Margins: Not meaningful because the filing reports no product revenue.
Changes versus the prior comparable period
- Six-month net loss narrowed by about $1.13 million, while operating expenses fell by about $0.71 million. Lower R&D spending—mainly reduced external costs associated with the completed EB01 Phase 2 study, lower share-based compensation and labor costs—was partly offset by higher spending on the EB05 Phase 3 study. G&A increased, principally due to professional fees.
- Other income rose, including $424,836 of 2023 SIF grant income, with no comparable-period grant income. Interest income declined as cash balances fell. The quarter also included $14,766 of miscellaneous income related to forgiveness of a CEBA loan that was repaid during the quarter.
- Cash at period-end was $2.80 million, compared with $7.47 million at March 31, 2023. Six-month financing proceeds were substantially lower than in the prior-year period.
- Common shares outstanding increased to 3,215,968 from 3,075,473 at September 30, 2023, including shares sold through the at-the-market program.
Outlook, risks and notable items
- EB05 (paridiprubart) is in an ongoing Phase 3 study for acute respiratory distress syndrome. During the quarter, Edesa began transitioning day-to-day trial management to a new clinical research organization, citing expected improvements in analytics, recruitment visibility and turnaround of trial results.
- Management said it plans to fund operations over the next 12 months using available cash, ATM proceeds, potential advances under its credit facility and reimbursements under the 2023 SIF agreement. It also expects substantial operating losses for at least several years and may seek additional equity, grants, debt or strategic financing. The filing warns that funding may not be available on acceptable terms or at all, and that development could be delayed, reduced or discontinued if financing is insufficient.
- The related-party facility is described as a C$10 million agreement with a C$3.5 million credit limit, available subject to a borrowing base, bearing interest at the CIBC U.S. base rate plus 3%, and maturing March 31, 2026. No funds had been drawn at March 31; standby charges were $25,000 for the six months.
- Aggregate contracted research and other service commitments were approximately $560,000. Separate license agreements include potential milestone obligations of up to $356 million and $18.4 million, plus up to $68.9 million under another agreement; these are contingent, not current reported liabilities. The company recorded $50,000 of expense for milestones under the latter agreement during the six months.
- Subsequent to quarter-end, Edesa collected $0.7 million on a receivable under the 2023 SIF agreement. The filing says disclosure controls were effective and reports no material change in risk factors or material legal proceedings.
Important facts for investors to verify
- Current cash runway and expected cash needs, including whether planned funding sources cover the next 12 months.
- EB05 Phase 3 enrollment, trial-management transition progress, timing of results and any resulting changes in trial spending.
- Actual availability and conditions for SIF reimbursements and advances under the related-party credit facility, including the borrowing base and repayment terms.
- Remaining ATM capacity, future share issuance and potential dilution; the filing reports approximately $6.5 million of capacity at March 31, 2024.
- Potential clinical, regulatory and commercial milestones under license agreements, and the contingent repayment terms of the SIF funding.